[go: up one dir, main page]

GB0425633D0 - Topical formulations for use in the treatment or prevention of dermatological conditions - Google Patents

Topical formulations for use in the treatment or prevention of dermatological conditions

Info

Publication number
GB0425633D0
GB0425633D0 GBGB0425633.5A GB0425633A GB0425633D0 GB 0425633 D0 GB0425633 D0 GB 0425633D0 GB 0425633 A GB0425633 A GB 0425633A GB 0425633 D0 GB0425633 D0 GB 0425633D0
Authority
GB
United Kingdom
Prior art keywords
prevention
treatment
topical formulations
dermatological conditions
dermatological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0425633.5A
Other versions
GB2420281A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stegram Pharmaceuticals Ltd
Original Assignee
Stegram Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stegram Pharmaceuticals Ltd filed Critical Stegram Pharmaceuticals Ltd
Priority to GB0425633A priority Critical patent/GB2420281A/en
Publication of GB0425633D0 publication Critical patent/GB0425633D0/en
Priority to PCT/GB2005/050209 priority patent/WO2006054119A1/en
Priority to EP05808838A priority patent/EP1865964A1/en
Publication of GB2420281A publication Critical patent/GB2420281A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB0425633A 2004-11-22 2004-11-22 Topical formulations for use in the treatment or prevention of dermatological conditions Withdrawn GB2420281A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB0425633A GB2420281A (en) 2004-11-22 2004-11-22 Topical formulations for use in the treatment or prevention of dermatological conditions
PCT/GB2005/050209 WO2006054119A1 (en) 2004-11-22 2005-11-22 Topical formulations for use in the treatment or prevention of dermatological conditions
EP05808838A EP1865964A1 (en) 2004-11-22 2005-11-22 Topical formulations for use in the treatment or prevention of dermatological conditions

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0425633A GB2420281A (en) 2004-11-22 2004-11-22 Topical formulations for use in the treatment or prevention of dermatological conditions

Publications (2)

Publication Number Publication Date
GB0425633D0 true GB0425633D0 (en) 2004-12-22
GB2420281A GB2420281A (en) 2006-05-24

Family

ID=33548645

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0425633A Withdrawn GB2420281A (en) 2004-11-22 2004-11-22 Topical formulations for use in the treatment or prevention of dermatological conditions

Country Status (3)

Country Link
EP (1) EP1865964A1 (en)
GB (1) GB2420281A (en)
WO (1) WO2006054119A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
EP1919290B1 (en) 2005-07-12 2014-01-22 Ampio Pharmaceuticals, Inc. Methods and products for treatment of diseases
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
NZ597030A (en) 2009-06-22 2013-10-25 Dmi Acquisition Corp Method for treatment of diseases
SG11201504380SA (en) 2012-12-19 2015-07-30 Ampio Pharmaceuticals Inc Method for treatment of diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE531437A (en) * 1953-08-26
US5869090A (en) * 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
FR2819409B1 (en) * 2001-01-17 2004-11-19 Sederma Sa USE OF DIOSGENINE IN COMPOSITIONS FOR COSMETIC OR DERMOPHARMACEUTICAL USE
FR2825277B1 (en) * 2001-05-30 2004-10-15 Oreal COSMETIC AND / OR DERMATOLOGICAL AND / OR PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE ENZIME 3, B-HSD IHNIBITOR COMPOUND
FR2831441B1 (en) * 2001-10-25 2003-12-26 Oreal COSMETIC USE OF DHEA DERIVATIVES
EP1509236A4 (en) * 2002-05-13 2008-07-30 Children S Hospital Los Angele TREATMENT AND PREVENTION OF ABNORMAL SCARING IN CHELOIDS AND OTHER INJURY OR INTERNAL INJURY OR LESIONS
AU2004203700B2 (en) * 2003-01-02 2007-06-21 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast

Also Published As

Publication number Publication date
GB2420281A (en) 2006-05-24
EP1865964A1 (en) 2007-12-19
WO2006054119A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
EP1727530A4 (en) Topical formulations for the treatment of skin conditions
PL378932A1 (en) Topical formulation of ivermectin for the treatment of dermatological conditions
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
HK1089376A1 (en) Formulation for use in the prevention and treatment of carbohydrate induced ; diseases and conditions
IL178012A0 (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer
IL180078A (en) 9-cis-retinal derivative for use in the treatment of 11-cis -retinal deficiency
PL2465493T3 (en) Topical compositions for the prevention and treatment of irritation of mucous cells
ZA200507346B (en) Topical formulation of ivermectin for the treatment of dermatological conditions
SI1761266T1 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
PT2083837E (en) Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent
EP1841397A4 (en) Formulations and treatments for trichology
TWI372047B (en) Topical pain relief compositions of n,2,3-trimethyl-2-isopropylbutamide and methods for using the same
IL187405A0 (en) Methods and compositions for the treatment of pain
ZA200705881B (en) Formulations and treatments for well-being
PL1933840T3 (en) Use of delmopinol in the treatment of acne
IL186022A0 (en) Dermatological compositions and salts for the treatment of dermatological diseases
HK1111599A1 (en) Pharmaceutical compositions for the treatment of cellulite
EP1720563A4 (en) Methods and compositions for the treatment of inflammation
GB0425633D0 (en) Topical formulations for use in the treatment or prevention of dermatological conditions
GB0427637D0 (en) Topical formulations for use in the treatment or prevention of skin cancers
GB2411834B (en) Composition for use in the treatment of dry skin conditions
ZA200710476B (en) Methods and compositions for the treatment of pain
GB2401044B (en) A composition for use in the treatment or prophylaxis of a skin condition in a subject
AU2003252187A8 (en) Topical composition for the treatment of inflammatory conditions of the skin
ZA200708279B (en) Dermatological compositions and salts for the treatment of dermatological diseases

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)